Sensitive and Chloroquine-Resistant Isolates of Plasmodiumfalciparum

Total Page:16

File Type:pdf, Size:1020Kb

Sensitive and Chloroquine-Resistant Isolates of Plasmodiumfalciparum Indian Jou rn al of Experimental Biology Vol. 38, November 2000, pp. 1129-1 133 In vitro schizontocidal activity of standard antimalarial drugs on chloroquine­ sensitive and chloroquine-resistant isolates of Plasmodiumfalciparum Poonam Sharma, C R Pillai* & Jayashri Devi Sharmat School of Environmental Sciences, Jawaharlal Nehru University, New Delhi II 0067, India E mai l: [email protected] *Malaria Research Centre (ICMR), 2 Nanak Encla ve, Delhi II 0009, India Received 8 Februmy 2000, Revised 2 August 2000 The expanding foci of multiple drug resistant malaria and emergence of different strains requires the reassessment of antimalari al activit y with various drugs. In vitro response of a chl oroquine sensiti ve and a chloroquine resistant isolate of P. falciparum to a group of 6 quinine derived and 3 artemisinin derived standard drugs has been screened, to evalu ate schi zontocidal aciti vt iy of the drugs. In a conventi onal test system the IC511s were derived from the log dose response curves and evalu ated by a ri gorous statistical interpretati on. Analysis by Tukey's test was signifi cant for the quinine related drugs (Q:s;O .O I) and excludes the stati sti cal significance of artemisinin related drugs in these isolates. The dose-responses of these two isolates vary with quinine derivatives, with some overlap at lower doses for the sensiti ve isolate than for the resistant one which manifests at higher doses. 4 In 1820 when th e structure of the principle alkaloid in a reaction catalysed by iron . Artemisinin quinine from Cinchona bark was identified, a large derivatives depend on many mechanism-based 5 number of its synthetic derivatives have been known approaches , and development of endoperoxide 6 to have effects singly and in combination with each antimalarial drugs . other. Since then innumerable attempts at finding the The only reliable definition of resistance in malaria effect of drugs from two major sources quinine and parasites is based on clinical and parasitological artemisinin have been undertaken for the di scovery of response in symptomatic patients and the in vitro their newer formulations and for the understanding of assay. It has the advantage of excluding several host their effect both, in vitro and their pharmacokineti cs factors when good correlations between in vivo and in 7 in clinical trial s. vitro tests can be found . Good correlation between in There is a specific interaction between the parasiti c vivo and in vitro resistance with chloroquine, 8 vesicles and antimalarial agents such as chloroquine amodi aquine and quinine have been reported . and the ability of chl oroquine to raise intra vesicular Mutations are also held responsibl e for chloroquine pH in the parasite at concentrations I-III 00 or less is resistance in Plasmodium falciparum and greatly based on the non-weak base effect. The other theories reduces the sensi ti vi ty to different classes of drugs of chloroquine action are the binding of chloroquine and increases the susceptibility to others like 9 to ferriprotophyrin IX (FP) and the intercalation of aminoquinolines . 1 chl oroquine to DNA • Quinine, mefloquine and The present study has been undertaken to evalu ate halofantrine show subtle deviations from this mode of the schizontocidal effects of various well known 2 action and do inhibit hemozoin product ion . antimalarials and the stati sticall y sign ificant The ethyl ether ex tracti on from Artemisia annua differences in the responses of two isolates of during 1971 and the use of q inghaosu in China Plasmodium falciparum, isolated from clinical cases showed excell ent parasiticidal activit/. The killing of of malaria as prevalent in India. parasi tes by artemi si nin and it s derivatives depends Materials and Methods on a selecti ve enhanced uptake of the drug in specific Quinine, quinaldine, quinacrine, chl oroquine, parasite membranes and itself becoming a free radical amodiaquine, halofantrine, artemisinin, artemether, arteether, primaquine and metronidazole are Sigma *Correspondent author chemicals. Malari a Research Centre P. falciparum 20 1130 INDIAN J EXP BIOL, NOVEMBER 2000 and MRC P. falciparum 76 were chloroquine The number of schi zonts with three or more nuclei sensiti ve and chloroquine resistant isolates of P. (merozoites) per 200 parasites were noted falciparum respectively, used. They were grown and microscopically. The values were compared between maintained in vitro by the standard method 10 and the control and test wells. The percent inhibition of sensitivity to standard drugs was tested foll owing schizont maturati on for each concentration of drug 1 12 star\dard methods 1. • The cultures of th ese isolates was calculated as: I 00 -a, where 'a' is the percent of were synchronized separately using Sorbitol schizont in the test wells as determined by a=zim, treatment and by centrifugation at 2000 rpm for 5 where z and m are mean number of schizonts per 200 min. at room temperature . Before centrifuging them, asexual parasites in test wel ls and control wells they were kept for I 0 min. at room temperature. This respectIv. e I y 14 . ensured killing of all other stages except young rings. From dose-response curves IC50 values (cone. at The supernatant was di scarded and th e pe ll et was which inhibition of parasite growth represent 50%) washed twice using incomplete (serum free) RPMI- were derived for each extract by plotting % inhibition 1640 medium i.e. centrifuged at 2000 rpm for 5 min. again st log concentration. Parasitaemia was adjusted to I- I .5 % for the assay by diluting with human fresh erythrocytes. The cell s Metronidazole, the standard antiamoebic drug was were diluted with compl ete medium to make 8 % al so tested in the same dose range (0.04-0.0 125 haematocrit. Individual drugs (I mg) were di ssolved 11 glml) for both the isolates of P. falciparum. in 50 111 DMSO, 50 111 ethyl alcohol and 900 111 RPMI- I 640 to give rise to I mg/ml concentration. Results These soluti ons were seri all y diluted two fold to The anti pl asmodial activity of the standard drugs in obtain a concentration of I !lglml which were micrograms/ml is shown in Tables I and 2 for both considered as the stock solution. The concentrati on of the isolates, MRC P. falciparum 20 and MRC P. ethanol was 0.05 % in the fin al stock solutions which falciparum 76 respectively. The quinine related was harmless to parasites. For determination of compounds show a fairly graded variation (F-value) intrinsic antimalarial activity, six 2- fold dilutions with lower doses in chloroquine sensitive isolate were prepared (0.4- 0.0 I 25 11 g/ml) to give MRC P . .falciparum 20 (Table I). In the chl oroquine concentration around the range of 50 % inhibitio n resistant isolate, MRC P. falciparum 76 the vari ati ons (lC50) for all the standard drugs used. During test, 50 are not so significant (Table 2). This is re fl ected in 111 culture medium (with or without drug) were the IC50 values which range I 0 times in chloroquine di spersed into a 96-well microtitre pl ate and next related drugs in CQ sensitive MRC P. falciparum 20 added 50!-ll of infected blood containing an initial and about three times more in CQ resistant MRC P. 1 parasitaemia of 1-1.5% and 8% haematocrit l. All .falciparum 76 (Table 4). The IC50 values with tests were done in triplicate. Artemisinin related drugs show a better value of 17 times in MRC P. falciparum 20, the sensitive isolate The plates were put in the candle j ar and a candl e and a lower effecti veness of three times less with the was lit. When the candle was at the point of resistant isolate MRC P. falciparum 76. The effect of extinction the stopcock was c losed. The candle jar primaquine and metronidazole fa ll s in a range far , was placed inside the incubator for 24-36 hr at 37 .5°C below even the dose-response with that of artemisinin depending upon the development of schi zonts in related drugs (Table 3). Table 4 ranks the IC50 values control wells. After incubation, the contents of the of these drugs with, artemether being the most test we ll s were harvested after removal of the effective and primaquine and metronidazole being the super"natant with a 50!-ll microcapillary tube and the least. Comparisons between the different drugs on the red blood cells deposited at the bottom of the we ll s basis of Tukey's test are given in Table 5. were transferred to a clean microscope slide to form a series of thick films. The resultant thick films were Discussion air-dried for 24 hr and then kept in the incubator set With c hl oroquine related drugs it may be possible at 37.5°C for 30 min, to ensure complete dryness. The to elaborate their mechanism of acti on better in slides were stained for 30 min in Gi emsa stain at a resistant strains than in sensiti ve ones. With dilution of 5-7 % in double di stilled water (v/v). artemi sinin related drugs these studies may be studied SHARMA et al.: DRUG SENSITIVITY IN ISOLATES OF PLASMODIUM FALCIPARUM 11 31 better with sensitive strain s than with the resistant pyronaridine, amodiaquine, chloroquine and qmnme ones. showed positive correlations suggesting cross By the Tukey's test the paired differences of % resistance amongst these drugs m vitro were 15 inhibiton for individual chloroquine related drugs significant at P~ 0.00 1 . which were significant at Q ~ 0.0 I are more The response of these two isolates to artemisinin significant in the sensitive isolate as shown in Tabl e related drugs shows a keener response by an overall 5.
Recommended publications
  • Halfanâ Brand of Halofantrine Hydrochloride Tablets
    HL:L4 PRESCRIBING INFORMATION HALFANâ brand of halofantrine hydrochloride Tablets WARNING: HALFAN HAS BEEN SHOWN TO PROLONG QTc INTERVAL AT THE RECOMMENDED THERAPEUTIC DOSE. THERE HAVE BEEN RARE REPORTS OF SERIOUS VENTRICULAR DYSRHYTHMIAS SOMETIMES ASSOCIATED WITH DEATH, WHICH MAY BE SUDDEN. HALFAN IS THEREFORE NOT RECOMMENDED FOR USE IN COMBINATION WITH DRUGS OR CLINICAL CONDITIONS KNOWN TO PROLONG QTc INTERVAL, OR IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED MEFLOQUINE, OR IN PATIENTS WITH KNOWN OR SUSPECTED VENTRICULAR DYSRHYTHMIAS, A-V CONDUCTION DISORDERS OR UNEXPLAINED SYNCOPAL ATTACKS. HALFAN SHOULD BE PRESCRIBED ONLY BY PHYSICIANS WHO HAVE SPECIAL COMPETENCE IN THE DIAGNOSIS AND TREATMENT OF MALARIA, AND WHO ARE EXPERIENCED IN THE USE OF ANTIMALARIAL DRUGS. PHYSICIANS SHOULD THOROUGHLY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRIBING HALFAN. DESCRIPTION Halfan (halofantrine hydrochloride) is an antimalarial drug available as tablets containing 250 mg of halofantrine hydrochloride (equivalent to 233 mg of the free base) for oral administration. The chemical name of halofantrine hydrochloride is 1,3-dichloro-a-[2-(dibutylamino) ethyl]- 6-(trifluoromethyl)-9-phenanthrene-methanol hydrochloride. The drug, a white to off-white crystalline compound, is practically insoluble in water. Halofantrine hydrochloride has a calculated molecular weight of 536.89. The empirical formula is C26H30Cl2F3NOHCl and the structural formula is 1 Inactive Ingredients Inactive ingredients are magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, sodium starch glycolate and talc. CLINICAL PHARMACOLOGY The interindividual variability in the pharmacokinetic parameters of halofantrine is very wide and has led to great difficulty in precisely determining the pharmacokinetic characteristics of this product. Following administration of halofantrine hydrochloride tablets in single oral doses of 250 mg to 1000 mg to healthy volunteers, peak plasma levels were reached in 5 to 7 hours.
    [Show full text]
  • Halofantrine and Primaquine for Radical Cure of Malaria in Irian Jaya, Indonesia D
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Public Health Resources Public Health Resources 1997 Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia D. J. Fryauff U.S. NAMRU-2 (Jakarta), Box 3, APO AP 96520-8132, U.S.A. J. Kevin Baird U.S. NAMRU-2 (Jakarta), Box 3, APO AP 96520-8132, U.S.A., [email protected] H. Basri U.S. NAMRU-2 (Jakarta), Box 3, APO AP 96520-8132, U.S.A. I. Wiady U.S. NAMRU-2 (Jakarta), Box 3, APO AP 96520-8132, U.S.A. U.S. NAMRU-2 (Jakarta), Box 3, APO AP 96520-8132, U.S.A. See next page for additional authors Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources Fryauff, D. J.; Baird, J. Kevin; Basri, H.; Wiady, I.; U.S. NAMRU-2 (Jakarta), Box 3, APO AP 96520-8132, U.S.A.; Bangs, M. J.; Subianto, B.; Harjosuwarno, S.; Tjitra, E.; Richie, T. L.; and Hoffman, S. L., "Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia" (1997). Public Health Resources. 376. http://digitalcommons.unl.edu/publichealthresources/376 This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Authors D. J. Fryauff; J. Kevin Baird; H. Basri; I. Wiady; U.S. NAMRU-2 (Jakarta), Box 3, APO AP 96520-8132, U.S.A.; M. J.
    [Show full text]
  • (Artemether / Lumefantrine 20Mg/120 Mg) Tablets
    SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 13 1. NAME OF THE MEDICINAL PRODUCT Lumartem (Artemether / Lumefantrine 20mg/120 mg) Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: 20 mg artemether and 120 mg lumefantrine. For a full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Yellow coloured, circular, uncoated, flat faced, bevelled edged, matt finished tablets with a break line on one side and plain on the other side. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indication Artemether 20 mg and Lumefantrine 120 mg Tablets is indicated for the treatment of uncomplicated cases of malaria due to Plasmodium falciparum in adults, children and infants of 5 kg and above. The most recent official guidelines on the appropriate use of antimalarial agents and local information on the prevalence of resistance to antimalarial drugs must be taken into consideration for deciding on the appropriateness of therapy with Artemether 20 mg and Lumefantrine 120 mg Tablets. Official guidance will normally include WHO (http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf) and local health authorities’ guidelines (see also sections 4.4 and 5.1). 4.2 Posology and method of administration Tablets for oral administration. Page 2 of 13 Number of Artemether 20 mg and Lumefantrine 120 mg Tablets for treatment according to weight bands st nd rd Weight range 1 day of 2 day of 3 day treatment treatment of treatment ≥ 5kg
    [Show full text]
  • Hydroxychloroquine (All Populations Monograph)
    3/17/2020 Clinical Pharmacology powered by ClinicalKey Hydroxychloroquine (All Populations Monograph) Indications/Dosage expand all | collapse all Labeled malaria rheumatoid arthritis malaria prophylaxis systemic lupus erythematosus (SLE) Off-Label, Recommended coronavirus disease 2019 (COVID-19) † severe acute respiratory syndrome coronavirus lupus nephritis † 2 (SARS-CoV-2) infection † polymorphous light eruption † † Off-label indication Per the manufacturer, this drug has been shown to be active against most strains of the following microorganisms either in vitro and/or in clinical infections: Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax. NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data only have not been established in adequate and well-controlled clinical trials. This drug may also have activity against the following microorganisms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, exclusion from this list does not necessarily negate the drug’s activity against the organism. For the treatment of malaria due to susceptible strains of P. falciparum, P. knowlesi†, P. malariae, P. ovale, and P. vivax https://www.clinicalkey.com/pharmacology/monograph/print?cpnum=300&type=0&printSections=monindi&printSections=monsup&printSections=mon… 1/87 3/17/2020 Clinical Pharmacology powered by ClinicalKey Oral dosage Adults 13 mg (10 mg base)/kg/dose [Max: 800 mg (620 mg base)/dose] PO, then 6.5 mg (5 mg base)/kg/dose [Max: 400 mg (310 mg base)/dose] PO at 6, 24, and 48 hours after the initial dose.[41806] [64059] For P.
    [Show full text]
  • Selection for Mefloquine Resistance in Plasmodium Falciparum Is Linked To
    Proc. Nati. Acad. Sci. USA Vol. 91, pp. 1143-1147, February 1994 Medical Sciences Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdrl gene and cross-resistance to halofantrine and quinine (drug reistance/malaria/P-glycoprotein/chloroquine) ALAN F. COWMAN*, DENISE GALATIS, AND JENNIFER K. THOMPSON The Walter and Eliza Hall Institute of Medical Research, Melbourne 3050, Australia Communicated by Gustav J. V. Nossal, October 11, 1993 (received for review September 8, 1993) ABSTRACT Two chloroquine-resistant cloned isolates of concomitant with the increase in chloroquine resistance was Plasmodiumfalciparum were subjected to mefloquine selection a decrease in the level of mefloquine resistance. In another to test if this resulted in alterations in chloroquine sensitivity study, selection for mefloquine resistance in the W2 isolate of and amplification ofthepfmdrl gene. The mefloquine-resistant P. falciparum showed a decrease in chloroquine resistance lines derived by this selection were shown to have amplified and (8) and amplification of the pfmdrl gene (4). All these results overexpressed the pfmdrl gene and its protein product (Pghl). suggested an inverse relationship between chloroquine and Macrorestriction maps of chromosome 5, where pfindrl is mefloquine resistance and a direct link with the level of Pghl encoded, showed that this chromosome has increased in size in expression. In this study we have selected two cloned lines response to mefloquine selection, indicating the presence of a of P. falciparum for increased mefloquine resistance and gene(s) in this area of the genome that confers a selective show that this has resulted in increased expression of the advantage in the presence ofmefloquine.
    [Show full text]
  • Malaria Chemotherapy & Drug Resistance
    This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this site. Copyright 2006, The Johns Hopkins University and David Sullivan. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided “AS IS”; no representations or warranties provided. User assumes all responsibility for use, and all liability related thereto, and must independently review all materials for accuracy and efficacy. May contain materials owned by others. User is responsible for obtaining permissions for use from third parties as needed. Malaria Chemotherapy and Drug Resistance David Sullivan, MD Eradication Attempts •Hookworm1909-1924: Sanitation and drug treatment; no reduction in 15 yrs. • Yellow Fever 1915-1930s: Mosquito control; discovery of natural reservoir in jungle animals ceased efforts. •Yaws1940-1960: Mass screening and penicillin; continued spread after best efforts. •Malaria1955-1975: DDT & chloroquine; $2 billion spent; insecticide resistance & African failure of DDT ceased efforts. • Smallpox 1967-1977: Successful vaccine heat stable and 99% effective as single dose; no hidden carriers. • Dracunculiasis 1986-?: 3.5 million to 100,000; Sudan - 605 of current cases; Nigeria increase; surveillance and water control • Polio 1985-?: Gone from western hemisphere; problematic in Congo, Sudan, and Afghanistan; vaccination- and surveillance- based control. If Not Eradication, Then Control! "At this time one must question the wisdom of even contemplating another eradication effort until the two eradication programs now in progress have been successfully concluded, until the lessons from those programs have been digested and until the savings from polio eradication have begun to be realized.
    [Show full text]
  • Treatment of Malaria in the United States a Systematic Review
    CLINICAL REVIEW CLINICIAN’S CORNER Treatment of Malaria in the United States A Systematic Review Kevin S. Griffith, MD, MPH Context Many US clinicians and laboratory personnel are unfamiliar with the diag- Linda S. Lewis, DVM, MPVM nosis and treatment of malaria. Sonja Mali, MPH Objectives To examine the evidence base for management of uncomplicated and severe malaria and to provide clinicians with practical recommendations for the diag- Monica E. Parise, MD nosis and treatment of malaria in the United States. VEN THOUGH ENDEMIC MALARIA Evidence Acquisition Systematic MEDLINE search from 1966 to 2006 using the has been eliminated from the search term malaria (with the subheadings congenital, diagnosis, drug therapy, epi- United States, it remains a lead- demiology, and therapy). Additional references were obtained from searching the bib- ing infectious disease world- liographies of pertinent articles and by reviewing articles suggested by experts in the Ewide. As a consequence, every year in treatment of malaria in North America. the United States an average 1200 cases Evidence Synthesis Important measures to reduce morbidity and mortality from of malaria are reported, almost all im- malaria in the United States include the following: obtaining a travel history, consid- ported, resulting in up to 13 deaths per ering malaria in the differential diagnosis of fever based on the travel history, and year.1 The unfamiliarity of US clini- prompt and accurate diagnosis and treatment. Chloroquine remains the treatment cians and laboratory personnel with ma- of choice for Plasmodium falciparum acquired in areas without chloroquine- resistant strains. In areas with chloroquine resistance, a combination of atovaquone laria and drug resistance patterns has and proguanil or quinine plus tetracycline or doxycycline or clindamycin are the best contributed to delays in diagnosis and treatment options.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Fatal Cardiotoxicity Related to Halofantrine: a Review Based on A
    Malaria Journal BioMed Central Research Open Access Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base Olivier Bouchaud*1, Patrick Imbert2, Jean Etienne Touze3, Alex NO Dodoo4, Martin Danis5 and Fabrice Legros6 Address: 1Service des maladies infectieuses et tropicales, Hôpital Avicenne AP-HP et Université Paris 13, 125 rue de Stalingrad, 93009 Bobigny, France, 2Service des maladies infectieuses et tropicales, Hôpital d'Instruction des Armées Bégin, 69 avenue de Paris, 94160 Saint-Mandé, France, 3Ecole de Santé des Armées du Val de Grâce, Place A. Laveran, Paris 75230, France, 4Centre for Tropical Clinical Pharmacology & Therapeutics, University of Ghana, Medical School Korle-Bu Teaching Hospital, Accra, Ghana, 5Service de Parasitologie Mycologie, Centre National de Référence du Paludisme, CHU Pitié-Salpêtrière, 47-83 boulevard de l Hôpital, 75651 Paris cedex 13, France and 6French Malaria National Reference Centre, Paris, France Email: Olivier Bouchaud* - [email protected]; Patrick Imbert - [email protected]; Jean Etienne Touze - [email protected]; Alex NO Dodoo - [email protected]; Martin Danis - [email protected]; Fabrice Legros - [email protected] * Corresponding author Published: 10 December 2009 Received: 17 July 2009 Accepted: 10 December 2009 Malaria Journal 2009, 8:289 doi:10.1186/1475-2875-8-289 This article is available from: http://www.malariajournal.com/content/8/1/289 © 2009 Bouchaud et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Integrated Structure-Transcription Analysis of Small Molecules Reveals
    bioRxiv preprint doi: https://doi.org/10.1101/119990; this version posted March 23, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Integrated Structure-Transcription analysis of small molecules reveals 2 widespread noise in drug-induced transcriptional responses and a 3 transcriptional signature for drug-induced phospholipidosis. 4 Francesco Sirci1, Francesco Napolitano1,+, Sandra Pisonero-Vaquero1,+, Diego Carrella1, Diego L. 5 Medina* and Diego di Bernardo*1, 2 6 7 1 Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli 8 (NA), Italy 9 2 Department of Chemical, Materials and Industrial Production Engineering, University of Naples 10 Federico II, Piazzale Tecchio 80, 80125 Naples, Italy 11 + These authors contributed equally to this work. 12 *co-corresponding authors 13 14 Abstract 15 We performed an integrated analysis of drug chemical structures and drug-induced transcriptional 16 responses. We demonstrated that a network representing 3D structural similarities among 5,452 17 compounds can be used to automatically group together drugs with similar scaffolds and mode-of- 18 action. We then compared the structural network to a network representing transcriptional 19 similarities among a subset of 1,309 drugs for which transcriptional response were available in the 20 Connectivity Map dataset. Analysis of structurally similar, but transcriptionally different, drugs 21 sharing the same mode of action (MOA) enabled us to detect and remove weak and noisy 22 transcriptional responses, greatly enhancing the reliability and usefulness of transcription-based 23 approaches to drug discovery and drug repositioning.
    [Show full text]
  • Metabolic Network Analysis Predicts Efficacy of FDA-Approved Drugs
    Chavali et al. BMC Systems Biology 2012, 6:27 http://www.biomedcentral.com/1752-0509/6/27 RESEARCHARTICLE Open Access Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease Arvind K Chavali1, Anna S Blazier1, Jose L Tlaxca1, Paul A Jensen1, Richard D Pearson2,3 and Jason A Papin1,4* Abstract Background: Systems biology holds promise as a new approach to drug target identification and drug discovery against neglected tropical diseases. Genome-scale metabolic reconstructions, assembled from annotated genomes and a vast array of bioinformatics/biochemical resources, provide a framework for the interrogation of human pathogens and serve as a platform for generation of future experimental hypotheses. In this article, with the application of selection criteria for both Leishmania major targets (e.g. in silico gene lethality) and drugs (e.g. toxicity), a method (MetDP) to rationally focus on a subset of low-toxic Food and Drug Administration (FDA)- approved drugs is introduced. Results: This metabolic network-driven approach identified 15 L. major genes as high-priority targets, 8 high- priority synthetic lethal targets, and 254 FDA-approved drugs. Results were compared to previous literature findings and existing high-throughput screens. Halofantrine, an antimalarial agent that was prioritized using MetDP, showed noticeable antileishmanial activity when experimentally evaluated in vitro against L. major promastigotes. Furthermore, synthetic lethality predictions also aided in the prediction of superadditive drug combinations. For proof-of-concept, double-drug combinations were evaluated in vitro against L. major and four combinations involving the drug disulfiram that showed superadditivity are presented.
    [Show full text]
  • A Strong Association Between Mefloquine And
    Am. J. Trop. Med. Hvg.. 5 I(S). 1994. pp. 645—658 Copyright 0 1994 by The American Society of Tropical Medicine and Hygiene A STRONG ASSOCIATION BETWEEN MEFLOQUINE AND HALOFANTRINE RESISTANCE AND AMPLIFICATION, OVEREXPRESSION, AND MUTATION IN THE P-GLYCOPROTEIN GENE HOMOLOG (pfindr) OF PLASMODIUM FALCIPARUM IN VITRO SHEILA A. PEEL, PATRICIA BRIGHT, BOYD YOUNT, JEAN HANDY, ANDRALPH S. BARIC Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina: Department of Microbiology and Immunology. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Abstract. Stepwise selection for increased mefloquine resistance in a line of Plasmo dium falciparum in vitro resulted in increased resistance to halofantrine and quinine, in creased sensitivity to chloroquine, and amplification and overexpression of the P-glyco protein gene homolog (pfmdrl). A point mutation (tynosine to phenylalanine) noted at amino acid 86 in pfmdrl in the mefloquine-nesistant line W2mef was amplified in more resistant lines derived from it by in vitro selection pressure with mefloquine. Conversely, lines selected for increased chloroquine resistance exhibited a nevertant phenotype that was sensitive to mefloquine and halofantrine. These lines also demonstrated increased sensitiv ity to quinine, loss of amplification of pfindrl. loss of the mefloquine/halofantrine phe nylalanine-86 mutation, and selection for a tyrosine-86 mutation previously associated with chlonoquine
    [Show full text]